Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility (Q24240654)

From Wikidata

Jump to navigation Jump to search

scientific article (publication date: 20 January 2010)

Language	Label	Description	Also known as
English	Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility	scientific article (publication date: 20 January 2010)

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20091537%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

0 references

1 reference

Europe PubMed Central

Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20091537%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

polycystic ovary syndrome

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

polycystic ovary

1 reference

based on heuristic

inferred from title

Robert J Norman

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20091537%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Thomas Tang

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20091537%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Jonathan M Lord

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20091537%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Ephia Yasmin

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20091537%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Adam H Balen

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20091537%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

20 January 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20091537%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Cochrane Database of Systematic Reviews

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20091537%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20091537%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

CD003053

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20091537%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

The effect of metformin on hirsutism in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Does metformin induce ovulation in normoandrogenic anovulatory women?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Extended-release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Effect of metformin pretreatment on pregnancy outcome of in vitro matured oocytes retrieved from women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Pathogenesis of polycystic ovary syndrome--the enigma unravels?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Ultrasound assessment of the polycystic ovary: international consensus definitions.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Is metformin the treatment of choice for anovulation in polycystic ovary syndrome?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Maternal morbid obesity and the risk of adverse pregnancy outcome.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Is insulin resistance an essential component of PCOS?: The influence of confounding factors.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Treatment of obesity: need to focus on high risk abdominally obese patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Molecular mechanisms of insulin resistance in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Screening women with polycystic ovary syndrome for metabolic syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Consensus on infertility treatment related to polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Troglitazone-induced liver failure: a case study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Negative lifestyle is associated with a significant reduction in fecundity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Obesity and weight loss in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Ultrasound examination of polycystic ovaries: is it worth counting the follicles?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

What role of estrogens in ovarian stimulation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Polycystic ovary syndrome: current and future treatment paradigms

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Polycystic ovary syndrome and fat distribution: the central issue?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Polycystic ovaries and associated clinical and biochemical features in young women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

The role of lifestyle modification in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Improving reproductive performance in overweight/obese women with effective weight management

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

The metabolic syndrome in young Korean women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Obesity and reproductive disorders in women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

The impact of obesity on reproduction in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Polycystic ovaries--a common finding in normal women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

The pathophysiology of polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Prevalence of the metabolic syndrome in Asian women with polycystic ovary syndrome: using the International Diabetes Federation criteria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Thiazolidinediones

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Fat and female fecundity: prospective study of effect of body fat distribution on conception rates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

21 January 2018

Type 2 diabetes and polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

The Finnish Diabetes Prevention Study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of the metabolic syndrome in German women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome--a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003053.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/14651858.CD003053.PUB4

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20091537%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20091537%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24240654&oldid=1588338334"